ES2094792T3 - Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos. - Google Patents

Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos.

Info

Publication number
ES2094792T3
ES2094792T3 ES91304047T ES91304047T ES2094792T3 ES 2094792 T3 ES2094792 T3 ES 2094792T3 ES 91304047 T ES91304047 T ES 91304047T ES 91304047 T ES91304047 T ES 91304047T ES 2094792 T3 ES2094792 T3 ES 2094792T3
Authority
ES
Spain
Prior art keywords
secretion
inhibition
compounds
agonistic activity
ht1a receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304047T
Other languages
English (en)
Inventor
Jaswant Singh Gidda
John Mehnert Schaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2094792T3 publication Critical patent/ES2094792T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION FACILITA UN METODO PARA INHIBIR LA SECRECCION DE ACIDO GASTRICO EN MAMIFEROS ADMINISTRANDO AGONISTA DE 5-HT1A O UNA SAL SUYA FARMACEUTICAMENTE ACEPTABLE.
ES91304047T 1990-05-04 1991-05-03 Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos. Expired - Lifetime ES2094792T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/519,388 US5096908A (en) 1990-05-04 1990-05-04 Method of inhibiting gastric acid secretion

Publications (1)

Publication Number Publication Date
ES2094792T3 true ES2094792T3 (es) 1997-02-01

Family

ID=24068110

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304047T Expired - Lifetime ES2094792T3 (es) 1990-05-04 1991-05-03 Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos.

Country Status (14)

Country Link
US (1) US5096908A (es)
EP (1) EP0455510B1 (es)
JP (1) JPH04270219A (es)
KR (5) KR0182791B1 (es)
AT (1) ATE145553T1 (es)
AU (1) AU640003B2 (es)
CA (1) CA2040248C (es)
DE (1) DE69123286T2 (es)
DK (1) DK0455510T3 (es)
ES (1) ES2094792T3 (es)
GR (1) GR3022466T3 (es)
HU (1) HU217835B (es)
PH (1) PH27223A (es)
ZA (1) ZA913363B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229410A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
ATE138374T1 (de) * 1991-11-18 1996-06-15 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamide zur behandlung von krankheiten des zentralnervensystems
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
GB9218113D0 (en) * 1992-08-26 1992-10-14 Lilly Industries Ltd Pharmaceutical compounds
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
CZ285829B6 (cs) * 1993-06-10 1999-11-17 Eli Lilly And Company Použití derivátu tetrahydrobenz [c,d]indolu pro výrobu farmaceutického prostředku vhodného pro ošetřování sexuální dysfunkce
IT1271404B (it) * 1993-08-09 1997-05-28 Hi Chem S P A Derivati ossimici dell'acido formilfenilacetamido-cefalosporanico
FR2712808B1 (fr) * 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
DE69533948T2 (de) 1994-10-21 2005-12-15 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-Rezeptor aktive Verbindungen
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO1997041090A1 (en) 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
CA2338037A1 (en) 1998-07-17 2000-01-27 Synaptic Pharmaceutical Corporation Compounds specific for the human .alpha.1d adrenergic receptor and uses thereof
AU2002218505A1 (en) * 2000-11-30 2002-06-11 Senju Pharmaceutical Co. Ltd. Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
DE10358004A1 (de) * 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
WO2010021149A1 (ja) * 2008-08-21 2010-02-25 武田薬品工業株式会社 酸分泌抑制スピロ化合物
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906757A (en) * 1959-09-29 Their preparation
US2922744A (en) * 1957-06-26 1960-01-26 Lilly Co Eli Therapeutic processes employing aminobenzodioxane medicaments
DE1668055B2 (de) * 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3346573A1 (de) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
AR241161A1 (es) * 1984-07-30 1991-12-30 Merrelll Dow Pharmaceuticals I "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida"
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
EP0306375A1 (fr) * 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
CA1331191C (en) * 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
CA1336911C (en) * 1988-06-03 1995-09-05 David Taiwai Wong Serotonin antagonists

Also Published As

Publication number Publication date
HUT60918A (en) 1992-11-30
DE69123286D1 (de) 1997-01-09
ZA913363B (en) 1993-01-27
KR0182791B1 (ko) 1999-05-01
KR910019615A (ko) 1991-12-19
KR100188373B1 (ko) 1999-06-01
EP0455510A2 (en) 1991-11-06
DK0455510T3 (da) 1997-04-28
DE69123286T2 (de) 1997-04-24
KR100189590B1 (en) 1999-06-01
EP0455510B1 (en) 1996-11-27
EP0455510A3 (en) 1992-05-06
AU640003B2 (en) 1993-08-12
KR100188372B1 (ko) 1999-06-01
CA2040248A1 (en) 1991-11-05
ATE145553T1 (de) 1996-12-15
JPH04270219A (ja) 1992-09-25
KR100188375B1 (en) 1999-06-01
HU217835B (hu) 2000-04-28
US5096908A (en) 1992-03-17
GR3022466T3 (en) 1997-05-31
PH27223A (en) 1993-05-04
AU7607991A (en) 1991-11-07
CA2040248C (en) 2001-06-19
HU911499D0 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
ES2094792T3 (es) Uso de compuestos con actividad agonista de receptor 5-ht1a para la inhibicion de la secrecion de acidos gastricos.
EP0342541A3 (en) Retroviral protease inhibitors
ES544523A0 (es) Un procedimiento para la preparacion de derivados de benzodiazefinas.
LT2063B (lt) Guanino dariniu arba ju farmaceutiskai tinkamu drusku gavimo budas
ES2120993T3 (es) Agentes antitromboticos.
FI961739L (fi) Amiinisuoloja klavulaanihapon valmistamiseksi
ATE223419T1 (de) Kondensierte thiadiazolderivate, verfahren zu ihrer herstellung und deren verwendung
MX9205455A (es) Procedimiento para la preparacion de diritromicina cristalina
CA1252106C (es)
ITRM930147A0 (it) Procedimento per la preparazione di sali dell'acido clavulanico. (caso 970-9808)
MX9205907A (es) Procedimiento para la preparacion de carboxilatos de hidroxifenilo
ES539942A0 (es) Un procedimiento para la preparacion de derivados de hidantoina.
ZA916918B (en) Amino acid analogs as CCK antagonists.
ES524895A0 (es) Un procedimiento para la preparacion de agentes antibacterianos unidos de dicarboxilato de 1,1-alcanodiol
ES2084733T3 (es) Nuevos substratos de beta-galactosidasa para el analisis cedia.
IT1219970B (it) Derivati amminoacridin-alfa,beta-(d)-e-(l)-n-glicosidici,loro sali e un procedimento per la preparazione di sali composti
SE8401492L (sv) Mellanprodukter for framstellning av h?712-receptorantagonister
MX9205408A (es) Metodo para tratar hipertension.
EP0260606A3 (en) Medicament for curing neurotic disturbance or disorder comprising sialocylglycerolipid
IT8422226A0 (it) Procedimento per la preparazione di l-fenilalaninametilestere cloridrato.
ES489925A1 (es) Procedimiento para la preparacion de n,n'-difenil-monohidra-zida de acido 2-(3-metil-3-butenil)-malonico
MX9204696A (es) Un procedimiento para la preparacion de acidos omega-arilalcanoicos.
MX9100343A (es) Procedimiento para la preparacion de analogos 6-acilo,7-acilo y 6,7-diacilo de forscolina y sus compuestos intermedios
MX21953A (es) Procedimiento para la preparacion de isomeros de compuestos de fosfonato.
ITMI910953A0 (it) Procedimento elettrochimico per la preparazione di lattami non sostituiti all'azoto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 455510

Country of ref document: ES